The agonizing itching is one of the most difficult symptoms to bear in patients with primary biliary cholangitis (PBC). It can have a far greater impact on everyday life, sleep and mental stability than the laboratory values of the underlying disease. New studies and congress papers from 2025 show that the therapeutic spectrum has expanded significantly in recent years. The focus today is on the targeted modulation of cholestatic mechanisms, in particular through inhibitors of bile acid transport and PPAR agonists, which not only have a favorable effect on the course of the disease but also on the symptom burden.
Autoren
- Tanja Schliebe
Publikation
- HAUSARZT PRAXIS
Related Topics
You May Also Like
- Early detection of type 1 diabetes
Detection of insulin autoantibodies as an early marker
- Type 2 diabetes
Smoking causes more than double the risk
- From symptom to diagnosis
Abdominal pain – Colitis
- Pathophysiology, cardiovascular consequences and metabolic interventions
Obesity accelerates cardiovascular ageing
- CKD: counteracting kidney progression and reducing the risk of CVD
Targeted intervention through a multifactorial approach
- COPD therapy
Drug therapy – Update 2025
- Atrial fibrillation: interdisciplinary effort is crucial
Managing risk factors and comorbidities in addition to rhythm control
- Casuistry